• Royalty Pharma kept 2026 Portfolio Receipts guidance at USD 3.33 billion-USD 3.45 billion, excluding transactions announced after May 6.
• Assumes Royalty Receipts growth of 4%-8%; milestones and other contractual receipts seen at about USD 60 million vs USD 128 million in 2025.
• Second-quarter Portfolio Receipts expected at USD 740 million-USD 760 million, versus USD 727 million in second-quarter 2025.
• Operating and professional cost payments forecast at 5.5%-6.5% of Portfolio Receipts; interest paid expected at USD 350 million-USD 360 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.